Mirati CFO Stelzer to depart

Mirati Therapeutics Inc. (NASDAQ:MRTX) announced that Aaron Ondrey will take over as interim CFO following the departure of CFO Laurie Stelzer on Sept. 8. Ondrey joined Mirati as SVP, financial planning and analysis in July 2022 from Arena Pharmaceuticals Inc.; Stelzer, who is leaving to pursue an external opportunity, will consult for the company through Oct. 31.

Exelixis Inc. (NASDAQ:EXEL) hired Amy Peterson as EVP, product development & medical affairs and CMO. Peterson was EVP and chief development officer and then president and COO at CytomX Therapeutics Inc. (NASDAQ:CTMX). She began her industry career at Genentech Inc., where she oversaw the IND submission and Phase I study of Tecentriq atezolizumab — a PD-L1 inhibitor with which Exelixis is studying its lead product, kinase inhibitor Cabometyx cabozantinib, as a combination to treat metastatic castration-resistant prostate cancer...